SC
AMLX icon

SummitTX Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

SummitTX Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09M Buy
227,690
+680
+0.3% +$10.5K 0.11% 220
2026
Q1 		$3.16M Buy
227,010
+8,611
+4% +$121K 0.1% 229
2025
Q4 		$2.64M Buy
218,399
+50,399
+30% +$685K 0.08% 263
2025
Q3 		$2.28M Buy
+168,000
New +$1.58M 0.09% 230

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SummitTX Capital's AMLX Position: Q2 2026 in Review

SummitTX Capital increased its Amylyx Pharmaceuticals (AMLX) stake by 0.3% in Q2 2026, buying an estimated $10.5K and bringing the position to 227,690 shares worth $4.09M. The position accounts for 0.11% of the portfolio, ranked #220.

SummitTX Capital first reported a position in AMLX in Q3 2025 and has held it in 4 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • SummitTX Capital held 227,690 shares of Amylyx Pharmaceuticals worth $4.09M as of Q2 2026.
  • SummitTX Capital bought 680 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $10.5K.
  • Amylyx Pharmaceuticals made up 0.11% of SummitTX Capital's portfolio in Q2 2026, its #220 holding.
  • SummitTX Capital first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.